Exceptional items in accounting are large, unusual gains or losses that a company breaks out separately so readers can tell ordinary operating performance apart from one-off events. The term is used more freely under UK and international reporting than under US rules, but every major framework requires some form of separate disclosure when a material item would otherwise distort the earnings picture. For anyone valuing a stock or reading a set of results, these items are the single biggest reason a headline profit number can mislead.
What Makes an Item Exceptional
An item earns the label when its size or nature falls outside the company’s ordinary, recurring activities and it is material, meaning large enough that burying it inside a general line would mislead an investor. A minor write-off on outdated office furniture does not qualify. A $200 million goodwill impairment almost certainly does.
IAS 1, the international presentation standard, lists the circumstances that typically trigger separate disclosure:
- Inventory write-downs to net realizable value and impairments of property, plant, and equipment, along with reversals of earlier write-downs.
- Restructuring costs such as severance and facility closures, and reversals of restructuring provisions that turn out to be unnecessary.
- Gains or losses on disposals of major property, equipment, or investments.
- Results from discontinued operations.
- Litigation settlements, regulatory fines, and other legal payouts or recoveries.
What ties the list together is that these events sit outside the normal cost of making products, paying staff, and running the business day to day. Closing three factories and laying off 5,000 workers is a fundamentally different transaction from paying the monthly electricity bill, and the income statement is expected to make that difference visible.
How the Accounting Standards Treat Them
Part of the confusion around exceptional items is that the label is not formally defined in most standards. The disclosure requirement exists everywhere; the exact wording and mechanics vary by framework.
IFRS
Under IAS 1 there is no line called “exceptional items.” Paragraph 97 requires that when items of income or expense are material, the entity discloses their nature and amount separately, and paragraph 98 provides the list of triggering circumstances above. Companies reporting under IFRS often use the word “exceptional” voluntarily to flag these items, but the standard itself just requires separate disclosure of anything material enough to warrant it.
UK GAAP (FRS 102)
UK practice has a longer history with the exceptional-items label. Under FRS 102, when items included in total comprehensive income are material, the company must disclose their nature and amount separately, either on the face of the income statement or in the notes. The Financial Reporting Council has observed wide variation in how companies present them, with many showing exceptional items on the face of the income statement alongside subtotals for profit before such items.
US GAAP
US standards do not use the term “exceptional items.” The FASB eliminated the extraordinary items classification in 2015 through ASU 2015-01. What remains is ASC 225-20, which requires material events or transactions that are unusual in nature or occur infrequently to be reported as a separate component of income from continuing operations, with nature and financial effects disclosed either on the face of the statement or in the notes. Those items cannot be shown net of tax or in any way that implies they are extraordinary.
Where They Appear on the Income Statement
Under current practice, exceptional items are usually embedded within the relevant line items rather than pulled out into their own section. A $50 million restructuring charge sits inside operating expenses and flows through the calculation of operating profit, not below it. The rationale is that these are real economic events that affected the period’s results, even if they are not expected to recur.
The value for a reader lives in the notes. That is where the company explains what happened, why it considers the item exceptional, and the exact amount. Anyone who only looks at the face of the statement sees a blended number. Anyone who reads the notes can identify the charge, understand its nature, and decide whether to exclude it when forecasting future earnings.
Some companies go further and present subtotals on the face of the income statement showing profit before exceptional items, sometimes labeled “underlying profit” or “adjusted operating profit.” The FRC has noted that a significant number of companies do this. It can be genuinely helpful, and it can also create opportunities for selective presentation.
Adjusted Earnings and the SEC’s Guardrails
When US public companies strip exceptional-type items out of their reported results to present adjusted earnings, they cross into non-GAAP financial measures, which trigger a specific set of SEC rules. Under Regulation G, any public company that discloses a non-GAAP measure must also present the most directly comparable GAAP measure and a quantitative reconciliation between the two.
The SEC has grown increasingly aggressive about policing how those adjusted numbers are built. Several practices can make a non-GAAP measure misleading under Rule 100(b):
- Excluding normal operating expenses. Stripping out recurring cash expenses that are necessary to run the business can violate the rule, and the SEC treats an expense as recurring if it happens repeatedly or occasionally, including at irregular intervals.
- Cherry-picking adjustments. Excluding a non-recurring charge while keeping a non-recurring gain from the same period is asymmetric and potentially misleading.
- Inconsistency across periods. Adjusting for a charge in the current period without making the same adjustment in prior-period comparatives can distort trends, and the SEC may require prior measures to be recast.
- Misleading labels. Using a GAAP-style label like “Gross Profit” for a figure that is not calculated the GAAP way can breach disclosure rules even when the math is disclosed elsewhere.
Item 10(e) of Regulation S-K adds another guardrail: a company cannot label a charge as “non-recurring,” “infrequent,” or “unusual” in its non-GAAP adjustments if a similar charge occurred within the prior two years or is reasonably likely to recur within the next two years. That rule directly targets the practice of dressing up persistent costs as one-time events.
Red Flags When Reading Exceptional Items
This is where most investors get burned. A company takes a $300 million restructuring charge and labels it exceptional. The market shrugs because it is “one-time.” Then the company takes another $250 million restructuring charge the following year. And another the year after that. At some point the restructuring is not a strategic pivot. It is the cost of doing business, and management is using the exceptional label to keep it out of the adjusted earnings that drive the stock price.
The classic version is called big bath accounting. A company facing a bad year loads as many charges as possible into that single period, writing down assets aggressively and reserving heavily for future costs. The current year looks terrible, but the company has effectively prepaid expenses that would otherwise hit later periods. Future depreciation drops because asset values have been slashed. Provisions that turn out to be excessive get reversed as gains in later years. The result is a manufactured earnings recovery that has nothing to do with improved operations.
A few patterns worth watching:
- Recurring “one-time” charges. If a company reports exceptional restructuring costs in three years out of five, treat them as ongoing expenses in your model.
- Write-downs on a schedule. Inventory write-downs or asset impairments arriving every other quarter suggest the company is systematically carrying assets too high and correcting through periodic exceptional charges.
- A widening gap between GAAP and adjusted earnings. When the spread between reported net income and the company’s preferred adjusted metric grows year after year, the adjustments are doing more of the work.
- Vague note disclosures. Broad descriptions like “strategic repositioning costs” without specifics often mean normal expenses have been swept into the exceptional bucket.
The SEC has brought enforcement actions on exactly this ground. In 2023, the SEC charged DXC Technology with providing materially misleading non-GAAP measures after the company allegedly inflated its adjusted results by improperly classifying certain expenses as non-GAAP adjustments related to acquisition activity. In 2024, the SEC challenged Commercial Metals Company’s exclusion of “mill operational commissioning costs” from its adjusted EBITDA, taking the position that those expenses were routine operating costs rather than one-time items.
How to Use Exceptional Items in Valuation
Exceptional items directly affect how a stock gets valued. A large non-recurring charge depresses reported net income, inflates the price-to-earnings ratio, and can make a fairly priced stock look expensive. A large exceptional gain does the opposite and makes an overpriced stock look cheap. Neither reflects what the business actually earns in a normal year.
Analysts handle this by calculating adjusted metrics that strip disclosed exceptional items out. Adjusted EBITDA and adjusted net income are the most common. The goal is to apply valuation multiples to the most representative earnings figure available, not the most flattering one.
The right approach is neither to accept the company’s adjusted numbers on faith nor to ignore exceptional items entirely. Read the notes, understand what actually happened, and form your own view of whether the item is genuinely non-recurring. A company that sold its headquarters at a $100 million gain did something it can only do once. A company booking $100 million in “exceptional” litigation costs while operating in a heavily regulated industry with a long history of lawsuits is telling you something different. The label is the same. The analytical treatment should not be.